Latest long-term debt for SOPH: $59M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), SOPH shows a long-term debt of $59M. That compares with $61M in the prior-year period — down 3.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SOPH's long-term debt is now $59M (was $61M) — a 3.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether SOPHiA Genetics SA is outperforming or lagging.
Tracking SOPH's long-term debt over time shows whether SOPHiA Genetics SA is scaling, shrinking, or reshaping that part of the business. The current reading is $59M That compares with $61M in the prior-year period — down 3.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has SOPHiA Genetics SA's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $59M) with ownership activity and broader fundamentals.
SOPHiA Genetics SA's long-term debt is $59M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.